Skip to Main Content

Once again, the Food and Drug Administration made a surprise move regarding an experimental medicine from Biogen — and Wall Street is reacting with a mix of skepticism and uncertainty about not only the prospects for the drug, but other issues concerning the agency, drug developers, and patients.

Specifically, analysts are turning their attention toward questions about whether this particular medicine can actually help patients — and in turn, whether Biogen shares will ever get a boost, assuming the drug is eventually approved. There is also uncertainty about FDA machinations and the broader implications for tackling central nervous system diseases.


What happened exactly?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.